TRACER

About TRACER

At TRACER we are specialized in first-in-human studies with the use of nuclear and optical molecular imaging techniques.

By labeling an antibody, small molecule, peptide, nanoparticle, protein, or any other compound of interest with a fluorescent dye or a radionuclide, fast in human data can be obtained with an indication of the potential efficacy of the novel drug, even before the classical phase 1-3 clinical trials. This can lead to a more efficient and less costly drug development process.

We assist our sponsors in the labeling of their lead compounds and execute first-in-human studies to visualize and quantify the biodistribution and pharmacokinetics of the compound. With this information a “ go/no-go” decision can be made before the compound proceeds to the next phase in clinical development where costs are larger and time is valuable.

Early in-human studies are approved by the EMA and FDA through the so-called principle of microdosing. It allows you to often skip (large) animal models and go straight into the patient population.

Keywords

• Cardiovascular Diseases
• Clinical Development
• Clinical Trials
• Drug Development
• Fluorescent Imaging
• In-Human Data
• Infection Diseases
• Inflammatory Diseases
• Microdosing
• Molecular Imaging
• Nuclear Imaging
• Oncology
• Optical Imaging
• Optical Tracers
• Phase I Study
• Phase Ii Study
• Phase Iii Study
• Proof Of Concept (Poc) Study
• Tracers

Address

• Headquarters

  Aarhusweg 2-19723JJ GroningenGroningen, Netherlands

Team by function

Based on 18 public job profiles as of 3 September 2026.

• Operations6
• Healthcare / Medical3
• Research / R&D3
• Executive / C-Suite2
• Founder / Owner1
• HR / People / Recruiting1
• Marketing1
• Sales1